Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This drug is a **combination product** containing **dropropizine** (a non-opioid antitussive/cough suppressant), **pseudoephedrine** (a sympathomimetic amine serving as a nasal decongestant via vasoconstriction through alpha- and beta-adrenergic receptor agonism[4]), and **brompheniramine** (an antihistamine that antagonizes histamine H1 receptors). The combination is indicated primarily for the symptomatic treatment of **cough** and **nasal congestion** associated with the **common cold** or **upper respiratory tract infections**, especially in pediatric populations[5][7]. - Dropropizine acts centrally to suppress cough reflex - Pseudoephedrine decreases nasal congestion by vasoconstriction in nasal mucosa - Brompheniramine relieves allergic symptoms by blocking H1 histamine receptors Primary use is for cough and cold symptom relief, typically as an oral syrup, such as in Dimetapp elixir[5][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on dropropizine + pseudoephedrine + brompheniramine.